uses JavaScript to provide the best possible experience for our content, but your browser has it disabled. Learn how to enable it here.


Posted November 03, 2022

Seller of CBD Warned for COVID-19 Claims

On November 1, 2022, the FDA issued a warning letter to Alternative Health Distribution LLC (d/b/a CannaAid) following a review of the company’s website, which found statements about the company’s cannabidiol (CBD) products to be drug claims.

The company’s CBD products were promoted with statements such as, “Recent analyses from numerous preliminary in vitro and animal studies have shown that cannabinoids in hemp, specifically CBD, can significantly reduce COVID-19’s ability to infect new cells – limiting inflammation in the lungs and possibly improving a patients’ quality of life during severe COVID-19 infection.” Its Immune Plus tincture was promoted with statements such as, “Here at CannaAid, we provide the best in what’s wellness. If you’re interested in trying CBD to mitigate the flu-like symptoms, check our online selection to find what best fits your needs — our Immune Plus tincture is a 4,200 mg. proprietary wellness blend made with CBGa and CBDa that just may do the trick!”

The company must respond to the agency within 15 days of receipt of the letter outlining any steps to address any violations.

For more information and tests of related products, see ConsumerLab’s CBD Review. Also see Do any supplements help with coronavirus (COVID-19)? Do supplements like vitamin D, zinc, vitamin C, or herbals work?

For more information, use the link below.

Warning: Alternative Health Distribution LLC d/b/a CannaAid

See related recalls and warnings:

Seller of CBD Warned for COVID-19 Claims

CBD Products Were Promoted to Treat Cancer and Alzheimer’s Without Proof, Says FTC

Maker of Care by Design CBD Settles Charges of Unsupported Claims

CBD Seller Warned for Drug and COVID-19 Claims

FDA Warns Five Companies for Selling CBD Supplements, Gummies and Creams with Delta-8 THC